RAS isoforms and mutations in cancer at a glance

By G. A. Hobbs, C. Der, K. Rossman. Journal of Cell Science, 2016

836 citations recorded by the source corpus.

Subfields: Molecular Biology

View Paper: https://www.semanticscholar.org/paper/c5ceab5ecdb7d4eb951f65dee842a08591b21fe3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. M. Bahar
2. D. Kim
3. Hyun Joon Kim

Citations in the corpus

• KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer (2018, neutral): “2C) (Cox et al. 2014; Stephen et al. 2014; Hobbs et al. 2016).”
• The frequency of Ras mutations in cancer (2020, background): “Ras activation causes a conformational change that allows engagement with more than 20 different proteins from 10 effector families (3).”
• Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies (2023, background): “12 All members of the RAF family interact with RAS; however, this contact alone is insuf fi cient to activate RAF.”
• Molecular targeted therapy: Treating cancer with specificity (2018, background): “For instance, 27% of cancer cases have been reported to possess rat sarcoma (RAS) gene mutation with 35–45% of this mutation found in colorectal cancer patients (Hobbs et al., 2016; Tan and Du, 2012).”